Page 55 - Demo

N-of-1 studies in rare genetic neurodevelopmental disorders53240. Araujo A, Julious S, Senn S. Understanding variation in sets of N-of-1 trials. PLoS One Epub 2016 Dec 1;11(12):e0167167.41. Senn S. Mastering variation: Variance components and personalised medicine. Statistics in medicine 2016;35(7):966-977. 42. Schmid, C. H., & Duan N. Statistical Design and Analytic Considerations for N-of-1 Trials. In: Design and Implementation of N-of-1 Trials: A User’s Guide 2014:33-53. 43. Gaasterland CMW, Jansen-van der Weide MC, Vroom E, et al. The POWER-tool: Recommendations for involving patient representatives in choosing relevant outcome measures during rare disease clinical trial design. Health Policy 2018;122(12):1287-1294. 44. Slade A, Isa F, Kyte D, et al. Patient reported outcome measures in rare diseases: A narrative review. Orphanet journal of rare diseases 2018;13(1):1-9.45. Regnault A, Burlina A, Cunningham A, et al. Development and psychometric validation of measures to assess the impact of phenylketonuria and its dietary treatment on patients’ and parents’ quality of life: the phenylketonuria–quality of life (PKU-QOL) questionnaires. Orphanet journal of rare diseases 2015;10(1):59.46. Ettema TP, Dröes RM, Lange J De, Mellenbergh GJ, Ribbe MW. A review of quality of life instruments used in dementia. Quality of life research 2005;14(3):675-686.47. Harris SL, Handleman JS, Belchic J, Glasberg B. The vineland adaptive behavior scales for young children with autism. Special Services in the Schools 1995;10(1):45-54. 48. Rojahn J, Schroeder SR, Mayo-Ortega L, et al. Validity and reliability of the Behavior Problems Inventory, the Aberrant Behavior Checklist, and the Repetitive Behavior Scale - Revised among infants and toddlers at risk for intellectual or developmental disabilities: A multi-method assessment approach. Research in developmental disabilities 2013;34(5):1804-1814.49. Shields RH, Kaat AJ, McKenzie FJ, et al. Validation of the NIH Toolbox Cognitive Battery in intellectual disability. Neurology 2020;94(12):1229-1240. 50. O’Mahony B, Skinner MW, Noone D, Page D, O’Hara J. Assessments of outcome in haemophilia - a patient perspective. Haemophilia: the Official Journal of the World Federation of Hemophilia 2016;22(3):208-209. 51. Gaasterland CMW, Van Der Weide MCJ, Roes KCB, Van Der Lee JH. Goal attainment scaling as an outcome measure in rare disease trials: A conceptual proposal for validation. BMC Medical Research Methodology 2019;19(1):227. 52. Csikszentmihalyi M, Larson R. Validity and reliability of the experience-sampling method. In: Flow and the foundations of positive psychology 2014;35-54. 53. Senn S. Sample size considerations for n-of-1 trials. Statistical Methods in Medical Research 2019;28(2):372-383.54. Craig P, Dieppe P, Macintyre S, Mitchie S, Nazareth I, Petticrew M. Developing and evaluating complex interventions: The new Medical Research Council guidance. BMJ 2008;337. 55. Bawden HN, MacDonald GW, Shea S. Treatment of children with Williams syndrome with methylphenidate. Journal of Child Neurology 1997;12(4):248-252.56. Byiers BJ, Dimian A, Symons FJ. Functional communication training in rett syndrome: A preliminary study. Americal Journal on Intellectual and Developmental Disabilities 2014;119(4):340-350. 57. Crook N, Adams M, Shorten N, Langdon PE. Does the Well-Being of Individuals with Down Syndrome and Dementia Improve When Using Life Story Books and Rummage Boxes? A Randomized Single Case Series Experiment. Journal of Applied Research in Intellectual Disabilities 2016;29(1):1-10. Annelieke Muller sHL.indd 53 14-11-2023 09:07